<DOC>
	<DOCNO>NCT02027298</DOCNO>
	<brief_summary>The primary purpose pilot study evaluate efficacy safety Abatacept subject Sjogren 's Syndrome ( SS ) . This clinical trial study enroll treat 15 subject active moderate severe inflammatory arthritis associate primary Sjogren 's syndrome ( pSS ) secondary Sjogren 's sybdrine ( sSS ) Rheumatoid Arthrits ( RA ) . All subject receive Abatacept weekly Subcutaneous ( SC ) dose . Subjects receive Abatacept SC injection 125 mg day 1 follow 125 mg SC weekly thereafter .</brief_summary>
	<brief_title>Abatacept Patients With Inflammatory Arthritis Associated With Sjögren 's Syndrome : Open-Label Phase II Study</brief_title>
	<detailed_description>Sjogren 's Syndrome ( SS ) common systemic autoimmune disease , include primary secondary form . About 30 % RA associate sSS ( 1 ) Tumor necrosis factor alpha inhibitor ( TNFa-Is ) try population without success . Abatacept ( CTLA4-Ig ) comprise ligand-binding domain CTLA4 plus human immunoglobulin represent novel therapeutic costimulation blocker modulate signal require full T cell activation . Studies show activated CD4 T cell play role pathogenesis SS , indicate Abatacept might useful therapeutic intervention SS . Subjects receive non-biologic immunosuppressive medication consist hydroxychloroquine , methotrexate ( MTX ) , sulfasalazine , leflunomide , time enrollment remain medication without dosage alteration . Efficacy Safety data collect time clinic visit . The treatment closing date occur 6 month enrollment subject . Subjects follow 1 , 2 , 3 , 4 , 5 , 6 month . Laboratory study associate clinical trial test potential autoantibody production systemic autoimmune disease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Diagnosis Sjogren 's Syndrome 2 . Patients least 18 year old 3 . Patients either pSS and/or sSS associate RA , must active moderate severe inflammatory arthritis define painful joint count ( ≥5 ) swell joint count ( ≥5 ) , DAS28 score &gt; 3.2 . 4 . One nonbiologic DMARD permit . 5 . These patient willing able comply treatment followup procedure . 6 . These patient willing able provide write informed consent . 7 . Both woman men child bear age must willing use effective mean birth control receiving treatment throughout participation study . Effective contraception method include abstinence , oral contraceptive ( birth control pill ) , IUD , diaphragm , Norplant , approve hormone injection , condom , medical sterilization . 1 . Patients exclude concomitant disorder require systemic glucocorticoid ( GC ) therapy ( prednisone &gt; 10 mg daily GC equivalent ) , organthreatening feature , investigational drug include biologics within 28 day study entry . 2 . History cancer diabetes mellitus 3 . Use tricyclic antidepressant anticholinergic 4 . Evidence active infection chronic infection include human immunodeficiency virus ( HIV ) , tuberculosis ( TB ) , hepatitis C , positive hepatitis B surface antigen . 5 . Patients latent TB treat isoniazid least 4 week prior receive study drug 6 . Radiographic evidence COPD , emphysema , and/or interstitial lung disease . 7 . Subjects pregnant nursing infant 8 . Patients cytopenia : platelet count &lt; 80,000/mm3 , absolute neutrophil count &lt; 1500/mm3 , hematocrit &lt; 20 % . 9 . Patients renal insufficiency define serum creatinine great equal 2.0 mg/dL creatinine clearance less equal 35 ml/min . 10 . Use illegal drug . 11 . A live vaccination few 4 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Abatacept</keyword>
	<keyword>Sjogren 's Syndrome</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>